Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores - Top-Institutions - MDSpire

Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores

  • By

  • Sami-Ramzi Leyh-Bannurah

  • Svitlana Boiko

  • Dirk Beyersdorff

  • Fabian Falkenbach

  • Jonas Ekrutt

  • Tobias Maurer

  • Markus Graefen

  • Mykyta Kachanov

  • Lars Budäus

  • May 2, 2022

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf
    Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf

    Hamburg, Germany

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Radiology
    • Oncology

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Radiology

  • #4

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Radiology
    • Urology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urology
    • Radiology

Original Source(s)

Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores

  • by Sami-Ramzi Leyh-Bannurah, Svitlana Boiko, Dirk Beyersdorff, Fabian Falkenbach, Jonas Ekrutt, Tobias Maurer, Markus Graefen, Mykyta Kachanov, Lars Budäus

  • May 2, 2022

Related Content

Sonographic twinkling artifact for diagnosis of acute ureteral calculus

Volumetric imaging: a potential tool to stage upper tract urothelial carcinoma

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?